Variability of growth in children starting antiretroviral treatment in Southern Africa

Pediatrics

Volumn 130, Issue 4, 2012, Pages

  Gsponer, Thomas ^a   Weigel, Ralf ^b,c   Davies, Mary Ann ^d   Bolton, Carolyn ^e,f   Moultrie, Harry ^g,h   Vaz, Paula ⁱ   Rabie, Helena ^j   Technau, Karl ^h,k   Ndirangu, James ^l   Eley, Brian ^d   Garone, Daniela ^m   Wellington, Maureen ⁿ   Giddy, Janet ^o   Ehmer, Jochen ^p   Egger, Matthias ^a   Keiser, Olivia ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b KAMUZU CENTRAL HOSPITAL   (Malawi)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ Paediatric Day Hospital   (Mozambique)

^j STELLENBOSCH UNIVERSITY   (South Africa)

^k UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^l UNIVERSITY OF KWAZULU NATAL   (South Africa)

^m MÉDECINS SANS FRONTIÈRES   (Switzerland)

ⁿ Newlands Clinic   (Zimbabwe)

^o MCCORD HOSPITAL   (South Africa)

^p SolidarMed ART Programme Zaka and Bikita Districts   (Zimbabwe)

more..

Author keywords

Antiretroviral therapy; Growth; HIV; Southern Africa

Indexed keywords

ANTIRETROVIRUS AGENT;

AGE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD GROWTH; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEIGHT FOR AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MOZAMBIQUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOUTH AFRICA; STUNTING; UNDERWEIGHT; WEIGHT FOR AGE; WEIGHT FOR HEIGHT; WORLD HEALTH ORGANIZATION; ZIMBABWE;

EID: 84867175493     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-3020     Document Type: Article

References (35)

1. Weigel R, Phiri S, Chiputula F, et al. Growth response to antiretroviral treatment in HIV-infected children: a cohort study from Lilongwe, Malawi. Trop Med Int Health. 2010;15(8):934-944
2. Nachman SA, Lindsey JC, Moye J, et al Pediatric AIDS Clinical Trials Group 377 Study Team. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2005;24(4):352-357 (Pubitemid 40525344)
3. Sutcliffe CG, van Dijk JH, Munsanje B, et al. Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: a cohort study. BMC Infect Dis. 2011;11(1):54
4. Arpadi SM. Growth failure in children with HIV infection. J Acquir Immune Defic Syndr. 2000;25(suppl 1):S37-S42
5. Miller TL. Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS. 2003;17(suppl 1):S130-S140 (Pubitemid 36667789)
6. Arpadi SM, Cuff PA, Kotler DP, et al. Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children. J Nutr. 2000;130(10):2498-2502
7. Benjamin DK Jr, Miller WC, Ryder RW, Weber DJ, Walter E, McKinney RE Jr. Growth patterns re fl ect response to antiretroviral therapy in HIV-positive infants: potential utility in resource-poor settings. AIDS Patient Care STDS. 2004;18(1):35-43 (Pubitemid 38435511)
8. Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45(3):311-317 (Pubitemid 47012378)
9. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS. 2004;18(14):1905-1913 (Pubitemid 39313206)
10. Song R, Jelagat J, Dzombo D, et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics. 2007;120(4). Available at: www.pediatrics. org/cgi/content/full/120/4/e856
11. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298(16):1888-1899 (Pubitemid 350005233)
12. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS. 2008;22(3):245-251 (Pubitemid 351380156)
13. Nyandiko WM, Ayaya S, Nabakwe E, et al. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. J Acquir Immune Defi c Syndr. 2006;43(4):418-425 (Pubitemid 44737098)
14. Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13
15. Kekitiinwa A, Lee KJ, Walker AS, et al Collaborative HIV Paediatric Study (CHIPS) Steering Committee; Mulago Cohort Team. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr. 2008;49(4):384-392
16. Naidoo R, Rennert W, Lung A, Naidoo K, McKerrow N. The influence of nutritional status on the response to HAART in HIV-infected children in South Africa. Pediatr Infect Dis J. 2010;29(6):511-513
17. Davies MA, Keiser O, Technau K, et al International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J. 2009;99(10):730-737
18. Blè C, Floridia M, Muhale C, et al. Efficacy of highly active antiretroviral therapy in HIV-infected, institutionalized orphaned children in Tanzania. Acta Paediatr. 2007;96(7):1090-1094 (Pubitemid 46934464)
19. Yotebieng M, Van Rie A, Moultrie H, Meyers T. Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. AIDS. 2010;24(1):139-146
20. Eley B, Davies MA, Apolles P, et al. Antiretroviral treatment for children. S Afr Med J. 2006;96(9 pt 2):988-993
21. The WHO Child Growth Standards. Child growth standards. Available at: www.who.int/childgrowth/en/. Accessed August 3, 2011
22. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Appl Stat. 1994;43(3):429-467
23. World Health Organization. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006
24. McGrath CJ, Chung MH, Richardson BA, Benki-Nugent S, Warui D, John-Stewart GC. Younger age at HAART initiation is associated with more rapid growth reconstitution. AIDS . 2011;25(3):345-355
25. Guillén S, Ramos JT, Resino R, Bellón JM, Muñoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J. 2007;26(4):334-338 (Pubitemid 46596659)
26. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics. 2002;109(2). Available at: www.pediatrics.org/cgi/content/full/109/ 2/e25
27. Griffiths PL, Rousham EK, Norris SA, Pettifor JM, Cameron N. Socio-economic status and body composition outcomes in urban South African children. Arch Dis Child. 2008;93(10):862-867
28. Steiner F, Kind C, Aebi C, et al. Growth in human immunode ficiency virus type 1-infected children treated with protease inhibitors. Eur J Pediatr. 2001;160(10):611-616 (Pubitemid 32939432)
29. Buchacz K, Cervia JS, Lindsey JC, et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics. 2001;108(4). Available at: www.pediatrics.org/cgi/content/full/108/4/e72
30. Campbell DI, Elia M, Lunn PG. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. J Nutr. 2003;133(5):1332-1338 (Pubitemid 36548703)
31. Miller TL, Agostoni C, Duggan C, Guarino A, Manary M, Velasco CA; HIV Working Group. Gastrointestinal and nutritional complications of human immunodeficiency virus infection. J Pediatr Gastroenterol Nutr. 2008;47(2):247-253
32. Camacho-Hubner C. Normal physiology of growth hormone and insulin-like growth factors in childhood. Available at: www.endotext.org/neuroendo/ neuroendo5a/neuroendoframe5a.htm. Accessed February 22, 2012
33. Palumbo P, Violari A, Lindsey J, et al. NVPvs LPV/r-based ART among HIV+ infants in resource-limited settings: The IMPAACT P1060 Trial. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011). Abstract 129LB. Available at: www.retroconference.org/2011/Abstracts/42501.htm. Accessed August 19, 2011
34. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE. 2009;4(6):e5790
35. Weigel R, Hochgesang M, Brinkhof MW, et al. Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi. BMC Infect Dis. 2011;11(31):31